FDA Approves Frontline Pembrolizumab/Chemotherapy in Advanced Mesothelioma
WEBSep 18, 2024 · Pembrolizumab plus chemotherapy is now an approved frontline treatment for patients with unresectable advanced or metastatic malignant pleural mesothelioma. Microscopic, photorealistic image of mesothelioma cells - Generated with Adobe Firefly.
Phase 3 Keytruda, Chemo Mesothelioma Trial Shows Promise
WEBJun 26, 2023 · Pharmaceutical company Merck says use of its immunotherapy drug Keytruda in conjunction with chemotherapy increases the survival rate for people with advanced pleural mesothelioma, according to the latest results of a phase 3 clinical trial.
FDA Approves Drug Combination for Treating Mesothelioma
WEBOct 2, 2020 · Today, the FDA approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of adults with malignant pleural mesothelioma that cannot be removed by surgery.
Understanding the new therapeutic options for mesothelioma
WEBSep 6, 2021 · However, in October, 2020, the FDA-approved first-line treatment for mesothelioma was changed to ipilimumab plus nivolumab due to the compelling data from CheckMate 743. Although RAMES offers another option, it is unclear where it fits into this new treatment paradigm.
FDA Approves Keytruda to Treat Pleural Mesothelioma
WEBSep 20, 2024 · Keytruda allows immune cells to recognize and attack cancer cells. This approach has helped many mesothelioma patients already. Keytruda joins other FDA-approved immunotherapy drugs for pleural mesothelioma. The combination of Opdivo® (nivolumab) and Yervoy® (ipilimumab) earned FDA approval in October 2020. It is now a standard treatment option.
FDA Approves Pembrolizumab/Chemo in Unresectable Pleural Mesothelioma
WEBSep 17, 2024 · A treatment regimen consisting of pembrolizumab (Keytruda) plus pemetrexed and platinum-based chemotherapy has earned FDA approval as a first-line therapy for patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM), according to a press release from the agency. 1 The regulatory agency approved pembrolizumab at a recommended dose of 200 mg every 3 weeks or …
Phase I Trial Improves Mesothelioma Survival More Than 200%
WEBJan 31, 2024 · Sellas Life Sciences reports its Phase I clinical trial showed improvement of overall survival in patients with pleural mesothelioma. The study focused on a new potential therapy called GPS (galinpepimut-S), an immunotherapy vaccine.
Immunotherapy approaches for malignant pleural mesothelioma
WEBJul 1, 2022 · In mesothelioma, a rare cancer with a dismal prognosis generally caused by exposure to asbestos, treatment with single or dual ICIs results in robust improvements in overall survival over...
Latest Mesothelioma T-Cell Clinical Trial Moves to Phase II
WEBOct 17, 2022 · The most recent T-cell therapy aimed at mesothelioma cancer has advanced to phase II of the clinical trial process, with researchers exploring its effectiveness when combined with an already approved immunotherapy duet.
FDA Grants Fast Track Designation to UV1 Vaccine Combo in …
WEBFeb 6, 2024 · The FDA has granted fast track designation to UV1, an investigational cancer vaccine, plus nivolumab (Opdivo) and ipilimumab (Yervoy) in the management of unresectable malignant pleural mesothelioma, according to a press release from Ultimovacs ASA, the developer of the vaccine. 1